-
Omeprazole A2845: Research Workflow and QC
2026-09-25
Omeprazole (A2845) provides a research tool for investigating H+,K+-ATPase inhibition and gastric acid secretion, with dossier-reported activity values to guide assay planning. It is for scientific research use only—not for diagnosis, treatment, or other medical use—and its water and ethanol insolubility make vehicle and solubility controls important.
-
Dantrolene Sodium Salt: Calcium Signaling, Carefully
2026-09-25
Dantrolene sodium salt is a ryanodine receptor antagonist for studying intracellular calcium release. This article connects its established RyR pharmacology with practical assay-design lessons from CRISPR repair research—while clearly separating evidence from hypotheses.
-
Mifepristone (RU486): From Receptor Biology to Translation
2026-09-24
Mifepristone (RU486) is a progesterone receptor antagonist with applications spanning reproductive biology and cancer research. This article outlines how to connect receptor engagement to meaningful phenotypes, interpret cross-tissue nuclear receptor findings carefully, and design more translational experiments with APExBIO’s B1511 research compound.
-
Prednisone Workflows for Lymphocyte Research
2026-09-24
Use Prednisone to build controlled lymphocyte assays that distinguish G1-phase arrest, IL-2 pathway suppression, and apoptosis rather than treating them as a single endpoint. This guide pairs practical dose-and-time screening with careful solvent controls and a clearly bounded lesson from digestive-metabolomics research.
-
Intranasal Sumatriptan in Pediatric ED Migraine Care
2026-09-23
A single-center retrospective study examined a pediatric emergency department pathway that placed intranasal sumatriptan among first-line migraine treatments. Pain scores declined across the treated cohort, while IV access was associated with longer stays and higher charges; the findings support feasibility but do not establish comparative efficacy or causation.
-
Hexose Diphosphate in Metabolic Flux Research
2026-09-23
Explore how hexose diphosphate supports metabolic flux, anaerobic glycolysis, and energy homeostasis research while remaining distinct from phosphoenolpyruvate-mediated cGAS–STING regulation. This guide translates biochemical context into practical assay and workflow decisions.
-
Rimonabant (SR141716) for CB1 Workflows
2026-09-22
Rimonabant (SR141716) gives researchers a selective CB1 blockade strategy for separating appetite, inflammatory, and neurobehavioral effects from non-cannabinoid mechanisms. This workflow-focused guide shows how to use SKU B1429 in receptor, cell, and translational experiments while avoiding solvent, selectivity, and interpretation pitfalls.
-
Gamma-linolenic acid (GLA): Mechanism & Workflows
2026-09-22
Gamma-linolenic acid (GLA) is an omega-6 polyunsaturated fatty acid investigated for LTB4-linked inflammatory signaling, cellular stress, and clinical inflammation. The C5518 research material provides defined identity, purity, solvent, storage, and assay benchmarks that support controlled anti-inflammatory research rather than direct therapeutic substitution.
-
Withania somnifera Digestion Mapped by LC–MS/MS
2026-09-21
A 2026 Journal of Agricultural and Food Chemistry study combines simulated gastrointestinal digestion, targeted LC–MS/MS, untargeted metabolomics, and molecular networking to examine how Withania somnifera leaf and root extracts change before absorption. Withaferin A and withanoside IV were comparatively labile, whereas withanolide A remained stable, demonstrating why botanical bioavailability studies must account for both compound identity and plant tissue.
-
Budesonide for Biomimetic Lung Permeability
2026-09-21
Build a research workflow that pairs Budesonide’s anti-inflammatory activity with biomimetic membrane-permeability screening. IAM-LC and OT-CEC provide complementary ways to prioritize airway inflammation experiments, troubleshoot formulation behavior, and separate membrane partitioning from biological response.
-
Elastic Hydrogel Microspheres for Disc Degeneration
2026-09-20
The reference study develops PMCCP, an elastic dual-network hydrogel microsphere that combines mechanically stable delivery with oxidative stimulus-responsive release of miR-155 and chitooligosaccharide. In cell and animal models of intervertebral disc degeneration, the platform reduced inflammatory and oxidative stress signals, limited nucleus pulposus cell apoptosis, and supported restoration of disc-cell function.
-
MFGE8–ANXA1–SMAD2/3 Targeting in Pancreatic Fibrosis
2026-09-19
This study links umbilical cord-derived mesenchymal stem cell extracellular vesicles to an MFGE8-dependent ANXA1–SMAD2/3 pathway that suppresses pancreatic stellate cell fibrotic activity. It also translates the mechanism into a recombinant MFGE8 nanoparticle platform, providing a mechanistic and delivery-oriented framework for chronic pancreatitis research.
-
GRK Control of M1 Receptor Biased Signaling
2026-09-18
This 2025 study uses BRET-based kinetic interaction profiling to show that GRK subtype behavior helps determine whether M1 muscarinic receptors favor G-protein or β-arrestin coupling. Its analysis of BQCA and other ligands connects receptor pharmacology with measurable changes in signaling-protein engagement, while also defining important limits for translating these findings to cognition or disease models.
-
AMPK–SQSTM1 Feedback Under Metabolic Stress
2026-09-18
The 2024 Autophagy study identifies a double-positive feedback loop between AMPK and SQSTM1/p62 that coordinates energy adaptation with NFE2L2/NRF2-dependent antioxidant defense. Its mechanistic model connects lysosomal deacidification, TFEB/TFE3 regulation, TAK1-mediated p62 phosphorylation, KEAP1 degradation, and AXIN–STK11–AMPK assembly, offering a framework for understanding metabolic adaptation in STK11- and KEAP1-altered lung cancer.
-
Ranolazine Research Workflows for Cardiac Ischemia
2026-09-17
Build reproducible Ranolazine assays around late sodium-current inhibition, metabolic remodeling, and quantitative injury readouts. This guide also shows how to use Ranolazine as a carefully bounded metabolic perturbation in liver-cell experiments inspired by new HBV–TBK1–autophagy findings.